While the authors suggest that the regimen combining a PD-1 antibody, an HDACi, and a VEGF antibody holds promise for treating patients with MSS/pMMR advanced colorectal cancer, the fatalities underline the potential risks associated with this combination therapy in treating colorectal cancer [106]. The gene discussed is VEGFA; the disease is colorectal cancer.